KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Raw Materials (2016 - 2025)

Historic Raw Materials for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $21.9 million.

  • Halozyme Therapeutics' Raw Materials fell 893.61% to $21.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $21.9 million, marking a year-over-year decrease of 893.61%. This contributed to the annual value of $21.9 million for FY2025, which is 893.61% down from last year.
  • Halozyme Therapeutics' Raw Materials amounted to $21.9 million in Q4 2025, which was down 893.61% from $19.0 million recorded in Q3 2025.
  • Halozyme Therapeutics' Raw Materials' 5-year high stood at $30.6 million during Q3 2024, with a 5-year trough of $6.0 million in Q1 2021.
  • For the 5-year period, Halozyme Therapeutics' Raw Materials averaged around $18.2 million, with its median value being $18.7 million (2025).
  • Per our database at Business Quant, Halozyme Therapeutics' Raw Materials surged by 13750.25% in 2023 and then tumbled by 3799.34% in 2025.
  • Halozyme Therapeutics' Raw Materials (Quarter) stood at $10.7 million in 2021, then grew by 29.24% to $13.8 million in 2022, then surged by 71.45% to $23.6 million in 2023, then rose by 1.56% to $24.0 million in 2024, then dropped by 8.94% to $21.9 million in 2025.
  • Its Raw Materials stands at $21.9 million for Q4 2025, versus $19.0 million for Q3 2025 and $17.8 million for Q2 2025.